<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084382</url>
  </required_header>
  <id_info>
    <org_study_id>JLU-AGKrawi_Spiru</org_study_id>
    <nct_id>NCT01084382</nct_id>
  </id_info>
  <brief_title>&quot; Arthrospira Platensis&quot; as Nutrition Supplementation for Female Adult Patients Infected by HIV in Yaoundé Cameroon</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frank Winter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Pasteur du Cameroun</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early interests in Arthrospira p. (Spirulina) were based on its high source of protein.&#xD;
      Recently, it has drawn attention for its therapeutic effects including anticancer properties,&#xD;
      antiviral and antibacterial properties as well as improvement of the immune system.&#xD;
&#xD;
      The aim of this study is to investigate the effect of a daily supplementation with Spirulina&#xD;
      for adult wife living with HIV/AIDS in Yaoundé.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies suggest that the micronutrient status determines the progression of the HIV&#xD;
      infection to AIDS. This phenomenon may be explained by a vicious cycle of malnutrition and&#xD;
      infection. Here, the immune system needs energy and micronutrients to adequately respond to&#xD;
      infection. Early interests in Arthrospira p. (Spirulina) were based on its high source of&#xD;
      protein. Recently, it has drawn attention for its therapeutic effects including reduction of&#xD;
      blood cholesterol, nephrotoxicity, anticancer properties, radiation protection, antiviral and&#xD;
      antibacterial properties as well here improvement of the immune system.&#xD;
&#xD;
      The aim of the three months Randomized, double blind and placebo Controlled Trial (RCT) is to&#xD;
      investigate the effect of a daily supplementation with Spirulina for adult wife living with&#xD;
      HIV/AIDS in Yaoundé. The trial will be experimental, prospective, and longitudinal on 70&#xD;
      patients. The study consists of two periods of three months.&#xD;
&#xD;
      The primary objective is to evaluate the efficacy of Spirulina on CD4+ T-lymphocyte count and&#xD;
      the viral load during the RCT. The second objective is to confirm the effect of Spirulina on&#xD;
      nutritional status markers: albumin, iron anemia, bioimpendenz, and BMI. The documentation of&#xD;
      the nutritional marker will depict the restorative potential of Spirulina on patients with&#xD;
      advanced HIV infection. Further data collected within a 24-hour recall will inform about the&#xD;
      Individual Dietary Diversity Score. Explorative objective is the following of three disease&#xD;
      outcomes of an HIV infection at four different time points, at t=0, 3, 6 months, and 1 month&#xD;
      after the trial. The three explorative outcomes are the immune status with CD3+, CD8+, CD38+&#xD;
      and IFN gamma, the oxidative status, and the patient's quality of life.&#xD;
&#xD;
      This trial will end by August 2010.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 10, 2010</completion_date>
  <primary_completion_date type="Actual">June 10, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 cell account</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual Dietary Diversity Score (IDDS)</measure>
    <time_frame>12-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life perception (WHOQOL-HIV)</measure>
    <time_frame>12-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune status (CD3+, CD8+, CD38+ and IFN gamma)</measure>
    <time_frame>12-24 wekks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurements (BMI, Bioimpedenz)</measure>
    <time_frame>12-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma redox potential (MDA,TAOS)</measure>
    <time_frame>12-24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arthrospira platensis supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein/Dextran supplemented</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arthrospira platensis</intervention_name>
    <description>Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.&#xD;
One group will so haved received Arthrospira platensis for 24 weeks.</description>
    <arm_group_label>Arthrospira platensis supplement</arm_group_label>
    <arm_group_label>Protein/Dextran supplemented</arm_group_label>
    <other_name>Group with supp.A</other_name>
    <other_name>Group with supp.B,</other_name>
    <other_name>for the first phase</other_name>
    <other_name>in the second all patients receive supp.C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirm Infection with HIV&#xD;
&#xD;
          -  aged≥ 18-49 years&#xD;
&#xD;
          -  BMI&lt; 23&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  under HAART&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  severe opportunistic infection requiring intensive medical care&#xD;
&#xD;
          -  active smoking&#xD;
&#xD;
          -  initiation of antioxidant vitamin therapy&#xD;
&#xD;
          -  hyperlipidemia&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  kidney/liver dysfunction&#xD;
&#xD;
          -  intractable diarrhea (at least six liquid stools daily)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital du jours</name>
      <address>
        <city>Yaounde</city>
        <state>Centre</state>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Hôpital du jours&quot; from the Central Hospital</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <link>
    <url>https://www.uni-giessen.de/fbz/fb09/institute/ernaehrungswissenschaft/prof/int-ern</url>
    <description>Working Group Homepage</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Frank Winter</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Arthrospira platensis</keyword>
  <keyword>female HIV patient</keyword>
  <keyword>Yaounde</keyword>
  <keyword>Redox potential</keyword>
  <keyword>Life quality</keyword>
  <keyword>female patient infected by HIV in Yaounde: Cameroon</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

